Abstract | PURPOSE: METHODS: This phase I multicenter, open-label, single-arm study enrolled adults in a 3 + 3 dose escalation design to receive MEDI-575 (3, 6, 9, 12, or 15 mg/kg) once weekly (QW) until toxicity or disease progression occurred. One 0.5-mg/kg dose was given before the first dose in the 3-mg/kg cohort to determine pharmacokinetics (PK) and pharmacodynamics under unsaturated conditions. After completion of dose escalation in the QW cohorts, patients were enrolled in two additional cohorts and received MEDI-575 25 or 35 mg/kg every 3 weeks (Q3W). Secondary measures included assessments of PK, immunogenicity, and antitumor activity. RESULTS: A total of 35 patients received MEDI-575 QW (n = 23) or Q3W (n = 12). Most treatment-related adverse events were grade 1 or 2 in severity across all dose levels, with fatigue (n = 12) and nausea (n = 8) being reported most frequently. With no reports of dose-limiting toxicities (DLTs), the MTD was not reached. MEDI-575 exhibited a nonlinear PK profile and increased plasma platelet-derived growth factor-AA levels in a dose-dependent manner with limited immunogenicity. Stable disease was reported as the best tumor response in 9 of 29 evaluable patients; however, no objective responses were reported. CONCLUSION: Administration of MEDI-575 QW or Q3W resulted in a favorable safety profile, including a lack of DLTs, but without evidence of antitumor activity in patients with refractory solid tumors.
|
Authors | Carlos R Becerra, Paul Conkling, Nicholas Vogelzang, Hilary Wu, Shengyan Hong, Rajesh Narwal, Meina Liang, Fatemeh Tavakkoli, Naimish Pandya |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 74
Issue 5
Pg. 917-25
(Nov 2014)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 25149088
(Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Tovetumab
- Receptor, Platelet-Derived Growth Factor alpha
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(adverse effects, pharmacokinetics, therapeutic use)
- Area Under Curve
- Cohort Studies
- Disease Progression
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Fatigue
(chemically induced)
- Female
- Humans
- Male
- Metabolic Clearance Rate
- Middle Aged
- Nausea
(chemically induced)
- Neoplasms
(drug therapy, metabolism, pathology)
- Receptor, Platelet-Derived Growth Factor alpha
(immunology)
- Survival Analysis
- Treatment Outcome
- Vomiting
(chemically induced)
|